Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy.

Although neoadjuvant chemotherapy (NAC) is associated with a survival advantage in pure urothelial (PUC) muscle-invasive bladder cancer (MIBC), the role of NAC is less clear in variant histology (VH) or urothelial carcinoma with divergent differentiation (UDD).